Bryophyllum · Kalanchoe · Anthroposophic medicine · Complementary medicine · Mental and behavioral disorders Summary Background: The use of preparations from Bryophyllum pinnatum for tocolysis (or to arrest labor) is supported by observations obtained mainly at empirical level, but also by preclinical experiments performed with uterus strips and myometrium cell lines. Furthermore, a retrospective matched-pair study revealed good tolerability and effectiveness. In anthroposophic medicine, however, Bryophyllum species are used for a broad spectrum of diagnoses. Here, we characterize the prescribing pattern of Bryophyllum preparations in a network of anthroposophic physicians in Germany. Methods: 38 primary-care physicians in Germany participated in the EvaMed network, a multi-center observational study. They documented anonymized prescriptions, diagnoses and demographic data (age and gender) for each consecutive patient between 01.01.2004 and 01.01.2010. Diagnoses were coded according to the 10th revision of the International Classification of Diseases (ICD-10). In the present analysis, all prescriptions of any Bryophyllum preparation in the resulting data bank were identified and the corresponding diagnoses were analyzed retrospectively. Results: A total of 4,038 prescriptions of Bryophyllum preparations were identified in the EvaMed data bank. A variety of preparations could be found, 77.7% of which were prepared from Bryophyllum plants exclusively and 22.5% were combinations. Bryophyllum preparations were often prescribed to treat 'mental and behavioral disorders' (ICD-10 F00-F99, 35.7%) and 'diseases of the skin and subcutaneous tissue' (L00-L99, 16.0%), followed by 'symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified diseases' (R00-R99, 15.2%) and 'diseases of the nervous system' (G00-G99, 9.7%). Conclusion: By revealing the use of Bryophyllum preparations in so many other indications than preterm delivery, our data clearly show the urgent need to conduct additional clinical trials. (ICD-10 F00-F99 , 35,7%) und «Krankheiten der Haut und der Unterhaut» (L00-L99, 16,0%), gefolgt von «Symptomen und abnormen klinischen und Laborbefunden, die anderenorts nicht klassifiziert sind» (R00-R99, 15,2%) und «Krankheiten des Nervensystems» (G00-G99, 9,7%) verordnet. Schlussfolgerung: Die Daten zeigen eine vielfältige Verordnung von Bryophyllum-Prä-paraten bei anderen Indikationen als bei vorzeitigen Wehen und legen dadurch die dringende Notwendigkeit nahe, zusätzliche klinische Studien durchzuführen.
medical expertise in the field of anthroposophic medicine. According to this commission, Bryophyllum preparations are to be used for the following indications [17] : vulnerability to specific types of functional disorders and recurring infections related to the metabolic system, preterm and early contractions, and in emergency situations of anxiety or other related mental problems and associated sleep disorders. In addition, some of the multiple combinations with Bryophyllum preparations are indicated for mood disorders, agitation, menopausal symptoms, premenstrual syndrome, obsessive-compulsive disorders, prostration, and shock consequences [17] . There are several similarities between these indications and those suggested in another reference work on anthroposophic medicine [18] , namely situations of agitation/anxiety, sleeping disorders, asthma, psychosomatic disorders, psoriasis, and neurodermitis. Anthroposophic physicians frequently rely on these 2 reference works to choose their anthroposophic medications, but it is not known whether these sources were also used by the physicians participating in the present study (see below).
The Evaluation of Anthroposophic Medicine (EvaMed) network aimed to evaluate the use of remedies from complementary and alternative medicine (CAM) in primary care with regard to prescribing patterns, efficacy, and safety [19] [20] [21] [22] [23] [24] . 38 German physicians participated in this network by entering patient data on age, gender, diagnosis, and treatments. The resulting data bank has been / is being used to determine which remedies are being prescribed in general [19] , which ones are prescribed for a certain diagnosis or group of diagnoses [20, 24] , for a defined patient group [22, 23] , and in order to characterize the prescribing pattern of a particular group of remedies [21] .
Until the present work, it was not known for which exact diagnoses Bryophyllum preparations are being prescribed in daily clinical practice in Germany. In this country, Bryophyllum preparations can be obtained over-the-counter and have been in some cases officially authorized and in others registered, always without specific indications. In this work, the EvaMed data bank was used retrospectively to characterize the prescribing pattern of preparations based on Bryophyllum plants. It is expected that this knowledge will help in designing future clinical studies to address the effectiveness of the treatment of other disorders than preterm contractions.
Methods
Physicians were recruited among the members of the German National Association of Anthroposophic Physicians (Gesellschaft Antroposophischer Ärzte in Deutschland; GAÄD), which implies that all of them were specialized in anthroposophic medicine. A total of 362 physicians were contacted and informed about the EvaMed network by standard mail and, in the event of no response, 4 weeks later by telephone. For a physician to be eligible to participate in the study, he/she had to have a minimum of 5 years of professional experience and his/her medical practice had to meet a number of technical requirements, such as the presence of a special computerized patient documentation system (DocExpert,
Introduction
Bryophyllum spp. have been used in ethno-medicine of the regions of origin -tropical Africa, tropical America, India, China, Australia [1] -for a long time and apparently with considerable success. In their countries of origin, leaves of these plants are used to treat jaundice [2] , inflammation, infections [3] , and hypertension, as well as bladder and kidney problems [4] . Furthermore, there are indications that extracts from leaves of plants of the genus Bryophyllum (family Crassulaceae) might have the following properties [1] : analgesic, antipyretic, sedative, central nervous system (CNS) depressant, muscle relaxant, gastroprotective, anti-inflammatory, antiseptic, anti-allergic, anti-anaphylactic, antileishmanial, antitumor, anti-ulcer, immunomodulating, and wound healing (see also [3, [5] [6] [7] ). Finally, extracts of whole plants have been shown to have hypoglycemic properties, which might be useful in the treatment of diabetes [6] .
In Europe, the use of remedies prepared from the species Bryophyllum is limited almost exclusively to anthroposophic medicine, a holistic medical system founded by Rudolf Steiner and Ita Wegman in the 1920s [8] . There are several different Bryophyllum preparations currently in use that are produced either from Bryophyllum pinnatum (Lamarck) Oken (synonym: Kalanchoe pinnata (Lamarck) Persoon), synonym: Bryophyllum calycinum (Salisbury) or from Bryophyllum daigremontianum (Hamet and Perrier) Berger (synonym: Kalanchoe daigremontiana Hamet and Perrier). To our knowledge, the only clinical trials performed so far with Bryophyllum preparations address their use in the treatment of women with preterm labor, i.e. for tocolysis [9] . The first studies suggesting that B. pinnatum could show good tolerability and effectiveness had several methodological limitations [10] [11] [12] . Later on, the effectiveness and tolerability of an aqueous extract of B. pinnatum leaves were compared with those of betamimetics, in a retrospective study in which data of patients with preterm contractions treated with B. pinnatum were matched with data of comparable patients treated with beta-agonists [13] . While the effectiveness was similar, B. pinnatum led to significantly fewer side effects. The use of preparations from B. pinnatum in the treatment of premature labor was supported by experiments performed first with a leaf aqueous extract using uterus strips [14] , and thereafter conducted with press juice of leaves both at organ [15] and at cell level [16] , always using experimental models that mimic uterus contractions in vitro.
Within anthroposophic medicine, the indications for which a given plant preparation is prescribed derive from hypotheses concerning the pathophysiological processes occurring in the human being and the physiological processes taking place in the plant. Depending on the part of the plant used to produce the preparation and on the pharmaceutical methods, the suggested indications can be different. In Germany Prescribing Pattern of Bryophyllum Preparations 295 used a browser-based interface to match individual diagnoses with the corresponding drugs or remedies that had been prescribed. Finally, study investigators checked the data for completeness (e.g., matching diagnoses with remedies). If necessary, the study center phoned the physicians and asked them to supply any missing data. Diagnoses were coded according to the 10th revision of the International Classification of Diseases (ICD-10). Prescribed drugs were documented using the German National Drug Code (German: Pharmazentralnummer; PZN). The data collection covered the period from January 2004 until January 2010 (6 years).
The present retrospective analysis is based on the EvaMed data bank. Prescriptions were included in this analysis if Bryophyllum or one of the corresponding national codes was mentioned and if under therapy at least 1 diagnosis was mentioned. Subgroup analyses were performed for patient gender, age (younger than 12 years, 12-29 years, 30-44 years, 45-59 years, 60-79 years, 80 years or older), as well as for the various Bryophyllum preparations. Statistical analysis was performed with SPSS 16.0 for Windows. Descriptive analysis was used to determine prescription rates. Means and standard deviations (SDs) were calculated for continuous data.
Results

Description of the Participating Physicians and Patients
A total of 4,038 prescriptions of various Bryophyllum preparations were identified (table 1), corresponding to 2,280 patients; these were on average 29.5 ± 22.27 years old and in DocConcept, TurboMed, Duria, AdamedPlus, Medistar), a local area network (LAN) connection, and Microsoft Windows and Internet Explorer (i.e., as client software).
A total of 38 physicians (10.5% of the physicians contacted, 6.3% of the approximately 600 physicians in GAÄD) fulfilled the various requirements, gave informed consent, and agreed to participate in this prospective, multicenter observational study. All of them became members of the EvaMed network, which aims to evaluate CAM remedies in usual care with regard to prescribing patterns, efficacy and safety [19, [22] [23] [24] . The participating physicians were from 12 of 16 German states, their average age was 48.0 ± 6.1 years and 55% of them were male; none was working in a health center. They prospectively documented anonymized prescriptions, diagnoses and demographic data (age and gender) for each consecutive patient and provided these administrative, secondary data to the EvaMed data bank. The recommendations for good practice in secondary data analysis (e.g. anonymization of data on prescriptions and diagnoses) developed by the German Working Group on the Collection and Use of Secondary Data [25] were applied in full. In addition, the study was approved by the data security office of the Community Hospital Havelhoehe, which is associated with the Havelhoehe Research Institute. As only administrative, anonymized data were used and no experimental research or intervention on patients was applied, no ethical approval was considered to be needed [26] .
Prescriptions for each consecutive patient were entered in the data set by the participating physicians using their existing computerized patient documentation system. These data were thereafter exported to the Quality Documentation Statistics System in Health Care (QuaDoSta) hosted in each practice [20] . After completing each export, participating physicians 35.7%) and 'diseases of the skin and subcutaneous tissue' (L00-L99, 16%), followed by 'symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified diseases' (R00-R99, 15.2%) and by 'diseases of the nervous system' (G00-G99, 9.7%). Table 2 also shows how the focus of the prescriptions varied with the age group. In the group younger than 12 years, a relatively high number of prescriptions for 'diseases of the skin and subcutaneous tissue' and lower use for 'mental and behavioral diseases' was observed. Prescriptions for symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified diseases were particularly frequent in the case of patients older than 80 years. Table 3 shows the diagnosis categories corresponding to most prescriptions of Bryophyllum preparations taken as a whole and to each of the 3 most commonly prescribed monopreparations of Bryophyllum plants. In the first case, the following categories corresponded to more than 5% of the total prescriptions (table 3) : pruritus (L29, 7.4%), sleep disorders (G47, 7.3%), depressive episodes (F32, 6.4%), other anxiety disorders (F41, 6.3%), symptoms and signs involving emotional state (R45, 5.9%), and atopic dermatitis (L20, 5.2%). Somewhat different pictures emerged for the specific preparations. B. pinnatum 50% powder seemed to be comparatively more often prescribed for depressive episodes and recurrent depressive disorder, other anxiety disorders, atopic dermatitis, essential hypertension, and preterm delivery. In contrast, Bryophyllum Argento cultum Rh (D3 aqueous dilutions) and, even more, Bryophyllum Argento cultum (alcoholic dilutions) were preferentially prescribed for pruritus. Bryophyllum Argento cultum Rh (D3 aqueous dilutions) was furthermore relatively often prescribed for (organic and non-organic) sleep disorders, symptoms and signs involving emotional state, atopic dermatitis, and (other) behavioral and emotional diseases with onset usually occurring in childhood and adolescence. Besides, for pruritus, Bryophyllum Argento cultum (alcoholic dilutions) seemed to be preferentially prescribed for somatoform disorders, other neurotic diseases, and other dermatitis.
Discussion
More than one third of the documented prescriptions of Bryophyllum preparations aimed at improving 'mental and behavioral disorders' (table 2). 3 other diagnosis groups corresponded to at least 10% of the prescriptions, namely 1) 'skin and subcutaneous tissue', 2) 'symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified', and 3) 'diseases of the nervous system'. The frequent prescriptions for diagnoses associated with the speciality of psychiatry (Fdiagnoses) even though there were no psychiatrists among the participating clinicians were not unexpected since more than the half of the participating physicians were general practitioners who often prescribe, for instance, antidepressants [27, 28] . most cases (71.9%) female. The majority (53.2%, n = 2,150) of the prescriptions were written by general practitioners, 15.1% (n = 609) by pediatricians, 12.7% (n = 514) by internists, 10.5% (n = 424) by dermatologists, 6.5% (n = 262) by gynecologists, and 2.0% (n = 79) by neurologists. As depicted in table 2, a variety of patient age groups were well represented, even though there was a predominance of young children (31.2% of the patients were younger than 12 years) and middle-aged adults (28.0% were 45-59 years old). Relatively fewer patients were teenagers/young adults (5.8% were 12-29 years old) or older than 60 years (13.6%).
Prescription Characterization
As shown in table 1, most prescribed preparations had been produced with the species B. pinnatum (94.8%), the rest with B. daigremotianum. Besides the preparations depicted, a single prescription of an additional product was identified, but not included in the present analysis (data not shown). The majority (77.7%; table 1) of the prescribed preparations were produced exclusively from Bryophyllum plants and are in this manuscript referred to as 'Bryophyllum monopreparations', in contrast to the medications prepared with additional substances, which are referred to as 'Bryophyllum combinations'. A considerable part of the former (those with names comprising the word 'cultum', 59.1%) were prepared from the third generation of plants whose first generation had been treated with dilutions of silver (Argento) or mercury (Mercurio) while the second and third generations were manured with the compost of the first one. This treatment is characteristic of the anthroposophic pharmacy and does not result in increased levels of the corresponding metals in the treated plants, as shown by atomic absorption (Mónica Mennet, personal communication). 1 preparation included, in addition to Bryophyllum plants, a homeopathic dilution of oyster shell (Conchae). B. daigremontianum (D3) preparations additionally comprised a D5 dilution of silver and a D5 dilution of bovine uterus. Whereas the preparations of B. pinnatum were produced from fresh leaves, those of B. daigremontianum derive from an aqueous mother tincture of leaves that had been submitted to a fermentation process according to the technical regulation 33 from the Homeopathic Pharmacopoeia (in German: Homöopathisches Arzneimittelbuch, HAB). Finally, the preparations Bryophyllum (alcoholic dilutions of the mother tincture), Bryophyllum Mercurio cultum (alcoholic dilutions), Bryophyllum Rh (D3 aqueous dilutions) and Bryophyllum Mercurio cultum Rh (D3 aqueous dilutions) are registered in Germany; all remaining ones are officially authorised.
Prescribing Pattern of Bryophyllum Preparations
The diagnoses corresponding to the prescriptions of all Bryophyllum preparations taken together -for all patients according to gender and age -are depicted in table 2. Taken as a whole, Bryophyllum preparations were most often prescribed to treat 'mental and behavioral disorders' (block F00-F99, Simões-Wüst/Jeschke/Mennet/Schnelle/ Matthes/von Mandach Although it is difficult at present to propose a rationale for most of the detected uses of Bryophyllum preparations, in some cases there is preclinical evidence suggesting therapeutic potential of extracts from leaves of these plants. Their use in the treatment of pruritus -whose standard treatment is based on antihistamines (H1 antagonists) -is one of these examples. Press juice of B. pinnatum leaves was shown to possess antihistamine activity by blocking H1, but not H2, receptors, an effect that has been allocated to a flavonoid fraction [36] . Furthermore, an extract from B. pinnatum leaves has been shown to down-regulate pro-anaphylactic inducing immune responses [37] and very recently to have potential in the treatment of allergic airway disease [38] .
Sleep disorders constitute a second example in which preclinical evidence might support the therapeutic use of extracts of Bryophyllum. Different fractions of the leaf extract of B. pinnatum have been shown to potentiate the pentobarbitoneinduced sleeping time in in vivo models, i.e. to possess a CNSdepressant action [39] . This neurosedative effect was corroborated by a later study that in addition revealed muscle-relaxant properties of a leaf extract of B. pinnatum [40] . Musclerelaxing effects of aqueous extracts from B. pinnatum leaves are particularly well-documented in the case of preterm uterus contractions both at the clinical level [13] and in vitro, using strips of myometrium [14, 15] .
Other promising properties of Bryophyllum preparations comprise anti-inflammatory and wound-healing effects of B. pinnatum leaves [5] , which were detected in an in vivo model and could justify their use in the treatment of various kinds of dermatitis, in particular that of atopic dermatitis, a chronic inflammatory skin condition. Moreover, hypotensive properties of B. pinnatum leaves have been demonstrated in an in vivo model [41] .
Conclusion
Bryophyllum preparations were prescribed by physicians participating in the EvaMed network for a broad spectrum of diagnoses, which is typical for anthroposophic preparations. The most frequent diagnosis groups were: 1) 'mental and behavioral disorders', 2) 'disorders of skin and subcutaneous tissue', 3) 'symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified', and 4) 'diseases of the nervous system'. Future research should focus on pragmatic clinical trials to investigate the effectiveness of Bryophyllum preparations in the treatment of the most relevant clinical disorders mentioned in this report, in particular of sleep and anxiety disorders, as well as of depressions and atopic dermatitis.
A major limitation of the present study is the lack of information on the tolerability and effectiveness of the treatment with the various Bryophyllum preparations. A further limitation of the study is the lack of any information on the daily dose and the duration of the application of the Bryophyllum preparations. Moreover, the data on the prescribing pattern have to be understood in the context of the specialties of the physicians participating in the present study: A different physician group composition would probably have led to a somewhat different weighting of the various diagnoses. Half of the participating physicians were general practitioners; therefore, this subgroup of physicians most markedly influenced the diagnosis spectrum. In the present work, the use of Bryophyllum preparations was not directly compared with that of other medications. Assuming, however, that the 4,038 identified Bryophyllum prescriptions were written at a homogeneous rate during the study period, the number of prescriptions per year would be approximately 673, which at least in 2005 [19] would correspond to about 0.9% of all prescriptions of anthroposophic medications. This estimated percentage is markedly inferior to the 9.4% that have been previously reported in a prospective cohort study on chronic diseases involving 131 medical practices in Germany [8] . It is worth noting that the physicians were free to prescribe multiple and different types of medications for 1 diagnosis. At least in 2005, anthroposophic medications corresponded to 41.8% of all medications prescribed by the physicians participating in this network of anthroposophic physicians, while conventional medications corresponded to 41.4% of the total [19] .
Several components have been identified in leaves from B. pinnatum preparations, which are likely to have biological activity, namely flavonoid glycosides [29, 30] , flavonoids [30] [31] [32] , bufadienolides [33, 34] , and phenols [35] . Previous work on the pharmaceutical characterization of an aqueous extract directly obtained from juice of B. pinnatum leaves and identical to the starting material to produce each of the three most commonly prescribed monopreparations of Bryophyllum plants (B. pinnatum 50% powder, Bryophyllum Argento cultum Rh D3 aqueous dilutions and Bryophyllum Argento cultum alcoholic dilutions) revealed the presence of flavonoids, cinnamic acid derivatives, and bufadienolides [15] . Even though these three preparations have B. pinnatum leaves as common plant material, their preparation methods as well as the available concentrations are different. The 50% powder is produced by mixing press juice of B. pinnatum with the same weight of lactose hydrate. In contrast, both preparations of Bryophyllum Argento cultum are homeopathic preparations. Bryophyllum Argento cultum alcoholic dilutions are produced from an alcoholic mother tincture that is homeopathically diluted (potentized) to the concentrations D2 (1%) and D3 (0.1%). Bryophyllum Argento cultum Rh is prepared from an aqueous mother tincture produced in a particular process in which the extraction temperature is changed rhythmically; thereafter, it is potentized at D3 (0.01%). The different ex-
